162 related articles for article (PubMed ID: 37615532)
21. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
Lee J; Park YH
Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
[TBL] [Abstract][Full Text] [Related]
22. Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy.
Falk M; Willing E; Schmidt S; Schatz S; Galster M; Tiemann M; Ficker JH; Brueckl WM
Curr Oncol; 2023 Jan; 30(2):1692-1698. PubMed ID: 36826091
[TBL] [Abstract][Full Text] [Related]
23. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
[TBL] [Abstract][Full Text] [Related]
24. Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer.
Mishima S; Shitara K
Expert Opin Biol Ther; 2021 Jul; 21(7):825-830. PubMed ID: 33798395
[No Abstract] [Full Text] [Related]
25. Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study).
Dowling GP; Toomey S; Bredin P; Parker I; Mulroe E; Marron J; McLoughlin O; Teiserskiene A; Power C; O'Shea AM; Greally M; Morris PG; Duke D; Hill ADK; Hennessy BT
BMC Cancer; 2024 Jan; 24(1):91. PubMed ID: 38233810
[TBL] [Abstract][Full Text] [Related]
26. Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer.
Ishii T; Shitara K
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1193-1201. PubMed ID: 34543577
[TBL] [Abstract][Full Text] [Related]
27. [Trastuzumab-deruxtecan monotherapy in HER2-activated advanced non-small cell lung cancer pre-treated with platinum-based chemotherapy with or without immunotherapy].
Rivier C; Lavaud P
Bull Cancer; 2024 Jun; 111(6):539-540. PubMed ID: 38553285
[No Abstract] [Full Text] [Related]
28. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843
[TBL] [Abstract][Full Text] [Related]
29. The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results.
Nakano K
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069146
[TBL] [Abstract][Full Text] [Related]
30. Optimizing Dosing of Trastuzumab Deruxtecan in
Hoe HJ; Solomon BJ
J Clin Oncol; 2023 Nov; 41(31):4849-4851. PubMed ID: 37694345
[No Abstract] [Full Text] [Related]
31. Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for
Azar I; Alkassis S; Fukui J; Alsawah F; Fedak K; Al Hallak MN; Sukari A; Nagasaka M
Lung Cancer (Auckl); 2021; 12():103-114. PubMed ID: 34675733
[TBL] [Abstract][Full Text] [Related]
32. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
33. Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring
Mazieres J; Lafitte C; Ricordel C; Greillier L; Negre E; Zalcman G; Domblides C; Madelaine J; Bennouna J; Mascaux C; Moro-Sibilot D; Pinquie F; Cortot AB; Otto J; Cadranel J; Langlais A; Morin F; Westeel V; Besse B
J Clin Oncol; 2022 Mar; 40(7):719-728. PubMed ID: 35073148
[TBL] [Abstract][Full Text] [Related]
34. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer.
Shitara K; Baba E; Fujitani K; Oki E; Fujii S; Yamaguchi K
Gastric Cancer; 2021 Jul; 24(4):780-789. PubMed ID: 33997928
[TBL] [Abstract][Full Text] [Related]
35. Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studies.
Takahashi S; Bando H; Kinoshita I; Modi S; Tsurutani J; Bang YJ; Sato Y; Nakatani S; Lee C; Sugihara M; Okuda Y; Iwata H
Jpn J Clin Oncol; 2024 Apr; 54(4):434-443. PubMed ID: 38231777
[TBL] [Abstract][Full Text] [Related]
36. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
Rugo HS; Bianchini G; Cortes J; Henning JW; Untch M
ESMO Open; 2022 Aug; 7(4):100553. PubMed ID: 35964548
[TBL] [Abstract][Full Text] [Related]
37. Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.
Bartsch R
Expert Opin Investig Drugs; 2020 Sep; 29(9):901-910. PubMed ID: 32701032
[TBL] [Abstract][Full Text] [Related]
38. Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan.
Neupane N; Thapa S; Bhattarai A; Ahuja K; Schlam I; Mittal A; Tolaney SM; Tarantino P
Curr Oncol Rep; 2023 Dec; 25(12):1467-1482. PubMed ID: 37938529
[TBL] [Abstract][Full Text] [Related]
39. Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.
van Berge Henegouwen JM; Jebbink M; Hoes LR; van der Wijngaart H; Zeverijn LJ; van der Velden DL; Roepman P; de Leng WWJ; Jansen AML; van Werkhoven E; van der Noort V; van der Wekken AJ; de Langen AJ; Voest EE; Verheul HMW; Smit EF; Gelderblom H
Eur J Cancer; 2022 Aug; 171():114-123. PubMed ID: 35716537
[TBL] [Abstract][Full Text] [Related]
40. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.
Mutlu L; Manavella DD; Bellone S; McNamara B; Harold JA; Mauricio D; Siegel ER; Buza N; Hui P; Hartwich TMP; Yang-Hartwich Y; Demirkiran C; Verzosa MSZ; Altwerger G; Ratner ES; Huang GS; Clark M; Andikyan V; Azodi M; Dottino PR; Schwartz PE; Santin AD
Mol Cancer Ther; 2023 Dec; 22(12):1404-1412. PubMed ID: 37676984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
